Original BioMedicals Co., Ltd. (6483.TWO)
TWD 11.75
(-4.08%)
TWD 11.75
(-4.08%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -29.49 Million | -30.41 Million | -24.93 Million | -23.94 Million | -26.38 Million |
| Net Income | -59.66 Million | -40.27 Million | -33.87 Million | -34.74 Million | -37.65 Million |
| Depreciation & Amortization | 8.73 Million | 7.93 Million | 8.64 Million | 11.88 Million | 13.46 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 6.71 Million | 344 Thousand | - | 221 Thousand | 842 Thousand |
| Change in working capital | 14.7 Million | 1.57 Million | -1.49 Million | -176 Thousand | 339 Thousand |
| Other non-cash items | 397 Thousand | 726 Thousand | 1.79 Million | -1.12 Million | -3.38 Million |
| Investing Cash Flow | -64.29 Million | 39.28 Million | -76.77 Million | - | 4.5 Million |
| Investments in PPE | -311 Thousand | -467 Thousand | -1.92 Million | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -99.8 Million | -34.93 Million | - | - | - |
| Sales/Maturities of investments | 34.93 Million | 74.85 Million | - | - | - |
| Other Investing Activities | 890 Thousand | -170 Thousand | -74.85 Million | - | 4.5 Million |
| Financing Cash Flow | 308.48 Million | -3.34 Million | 102.06 Million | 9.22 Million | 18.78 Million |
| Debt repayment | -3.84 Million | -3.34 Million | -2.95 Million | -2.77 Million | -2.75 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 312.33 Million | - | - | - | - |
| Other Financing Activities | 312.33 Million | - | 105.02 Million | 12 Million | 21.54 Million |
| Accounts receivables | -93 Thousand | 39 Thousand | -44 Thousand | - | -12 Thousand |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -2.16 Million | 384 Thousand | -1.44 Million | -176 Thousand | 351 Thousand |
| Cash at beginning of period | 13.98 Million | 8.46 Million | 8.09 Million | 22.81 Million | 25.92 Million |
| Cash at end of period | 228.67 Million | 13.98 Million | 8.46 Million | 8.09 Million | 22.81 Million |
| Capital Expenditure | -311 Thousand | -467 Thousand | -1.92 Million | - | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 214.69 Million | 5.52 Million | 362 Thousand | -14.71 Million | -3.1 Million |
| Free Cash Flow | -29.81 Million | -30.88 Million | -26.85 Million | -23.94 Million | -26.38 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -17.15 Million | -17.15 Million | -18.59 Million | -59.66 Million | -18.59 Million | -11.23 Million |
| Depreciation & Amortization | 2.08 Million | 2.08 Million | 2.27 Million | 8.73 Million | 2.27 Million | 2.09 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 3.09 Million | 6.71 Million | 3.09 Million | 259.5 Thousand |
| Change in working capital | -807 Thousand | -807 Thousand | -833.5 Thousand | 14.7 Million | -833.5 Thousand | -297 Thousand |
| Other non-cash items | -7.72 Million | -7.72 Million | 9.3 Million | 397 Thousand | 9.3 Million | -821 Thousand |
| Investing Cash Flow | -5.12 Million | -5.12 Million | -40.07 Million | -64.29 Million | -40.07 Million | 7.93 Million |
| Investments in PPE | -170 Thousand | -170 Thousand | -155.5 Thousand | -311 Thousand | -155.5 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -9.9 Million | - | - | -99.8 Million | - | - |
| Sales/Maturities of investments | - | - | - | 34.93 Million | - | - |
| Other Investing Activities | -4.95 Million | -4.95 Million | -39.92 Million | 890 Thousand | -39.92 Million | 7.93 Million |
| Financing Cash Flow | 410 Thousand | 410 Thousand | 155.15 Million | 308.48 Million | 155.15 Million | -912 Thousand |
| Debt repayment | - | - | - | -3.84 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.91 Million | - | - | 312.33 Million | - | - |
| Other Financing Activities | 410 Thousand | 410 Thousand | 155.15 Million | 312.33 Million | 155.15 Million | -912 Thousand |
| Accounts receivables | -60.5 Thousand | -60.5 Thousand | -55.5 Thousand | -93 Thousand | -55.5 Thousand | 9000.00 |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -746.5 Thousand | -746.5 Thousand | -778 Thousand | -2.16 Million | -778 Thousand | -306 Thousand |
| Cash at beginning of period | 228.67 Million | - | - | 13.98 Million | - | - |
| Cash at end of period | -28.31 Million | -28.31 Million | 110.32 Million | 228.67 Million | 110.32 Million | -2.97 Million |
| Capital Expenditure | -170 Thousand | -170 Thousand | -155.5 Thousand | -311 Thousand | -155.5 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -256.99 Million | -28.31 Million | 110.32 Million | 214.69 Million | 110.32 Million | -2.97 Million |
| Free Cash Flow | -23.77 Million | -23.77 Million | -4.9 Million | -29.81 Million | -4.9 Million | -9.99 Million |
1846
HLGN
0JWC
300775
3710
ROSSARI